Local Institution

Atlanta, Georgia 30342

0 studies enrolling now · 28 studies all time

What they study most

Acute Coronary Syndromes, Alzheimer Disease, Bipolar Disorder, Bladder Cancer, Bladder Neoplasms, Blast Crisis, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Diabetes Mellitus II, HIV Infections, Hepatic Cirrhosis, Hypertension

Studies at this site

• A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder — Completed
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis — Completed
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients — Stopped early
• Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type — Completed
• Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders — Completed
• Study of Aripiprazole in Patients With a History of Bipolar Disorder — Completed
• A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder — Completed
• Aripiprazole Open-Label, Safety and Tolerability Study — Completed
• Aripiprazole in Children and Adolescents With Bipolar I Disorder — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• Atazanavir for HIV Infected Individuals: An Early Access Program — NO_LONGER_AVAILABLE
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed
• Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery — Completed
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer — Stopped early
• Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen — Completed
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate — Completed
• A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen — Completed